Diagnostics company Protagen and biopharmaceutical firm SuppreMol announced a collaboration this week to identify therapy-related biomarkers in patients with systemic lupus erythematosus.
According to a statement from SuppreMol CEO Peter Buckel, the company plans to use Protagen's UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of its lead therapeutic SM101.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
